NCT04730973 (CARUSO) is a Phase 4 clinical trial of Evolocumab in Carotid Artery Disease, sponsored by Azienda Ospedaliera Ordine Mauriziano di Torino.

Who is sponsoring NCT04730973?

NCT04730973 is sponsored by Azienda Ospedaliera Ordine Mauriziano di Torino.

What drugs are being tested in NCT04730973?

Interventions in NCT04730973: Evolocumab, lipid-lowering therapy (LLT).

What condition does NCT04730973 study?

NCT04730973 studies Carotid Artery Disease.

Is NCT04730973 still recruiting?

NCT04730973 is currently status unknown. Last updated 28 July 2021.

Last reviewed 2021-07-28 · How we verify

NCT04730973: CARUSO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CARotid plaqUe StabilizatiOn and Regression With Evolocumab.

Status unknown Phase 4 Last updated 28 July 2021

What this trial tests

Phase 4 trial testing Evolocumab in Carotid Artery Disease in 130 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Azienda Ospedaliera Ordine Mauriziano di Torino
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	130
Start date	1 March 2021
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	1 location across Italy

Drugs / interventions tested

Evolocumab (EVOLOCUMAB) — full drug profile →
lipid-lowering therapy (LLT)

Conditions studied

Carotid Artery Disease — all drugs for Carotid Artery Disease →

Sponsor

Azienda Ospedaliera Ordine Mauriziano di Torino — full company profile →

Who can join

Adults 18 to 80, any sex, with Carotid Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque morphological stabilization and regression as compared to traditional lipid lowering therapy (LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12 months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and cardiac events at 12 and 24 months

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients.
Ilut S, Pirlog BO, Pirlog R, Nutu A, et al · · 2022 · cited 7× · PMID 36142135 · DOI 10.3390/ijms231810221

Verify or expand the search:

Other trials of Evolocumab

Trials testing the same drug.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT06284564 — A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients Wi · Phase 2 · active not recruiting
NCT06134635 — Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke · unknown
NCT05974345 — In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established C · completed

Other recruiting trials for Carotid Artery Disease

Currently open trials in the same condition.

NCT07200180 — Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery · Phase 3 · recruiting
NCT02850588 — SVS VQI TransCarotid Revascularization Surveillance Project · recruiting
NCT01597453 — NOR-SYS: The Norwegian Stroke in the Young Study · NA · active not recruiting

Other Azienda Ospedaliera Ordine Mauriziano di Torino trials

Trials by the same sponsor.

NCT05949476 — Influence of Ozone Therapy on Postoperative Pain Relief in the Surgical Treatment of Lower Third Molars: Randomized Cont · NA · unknown
NCT07164209 — The Remeasure Trial · NA · completed
NCT05762042 — Comparison of the Efficacy and Tolerability of Femal Versus Placebo · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04730973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Ordine Mauriziano di Torino
Last refreshed: 28 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04730973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing